| (USD) | Dec 2022 | Q/Q |
|---|---|---|
| Revenue | 61.5MM | +3% |
| Gross Profit | 43MM | +0% |
| Cost Of Revenue | 18.5MM | +11% |
| Operating Income | -8.5MM | -22% |
| Operating Expenses | 51.5MM | -4% |
| Net Income | -7.9MM | -26% |
| R&D | 9.5MM | +5% |
| G&A | 41.6MM | -6% |
| Amortization | 345K | -0% |
| Interest Expense | 404K | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.
It's not a stretch to say that Cardiovascular Systems, Inc.'s ( NASDAQ:CSII ) price-to-sales (or "P/S") ratio of 3.5x...
Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.
ST. PAUL, Minn., April 03, 2023--CARDIOVASCULAR SYSTEMS, INC. COMPLETES ENROLLMENT OF ECLIPSE CLINICAL TRIAL
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.